Payment overview · 2025
General Payments
$944.67
50 reported records · 16 companies
Healthcare provider profile · identity verified
Naketa Thomas, M.D
Allopathic & Osteopathic Physicians|Family Medicine · MYRTLE BEACH, SC · NPI 1003365859
Verified facts
What the public records show
CMS Open Payments records show Naketa Thomas, M.D received $944.67 in general payments during 2025 across 50 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Farxiga, Ozempic, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Creon by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 620 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Lantus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $238.72 | 25.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $187.45 | 19.8% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $180.35 | 19.1% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $95.14 | 10.1% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $38.45 | 4.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.92 | 3.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.63 | 2.7% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $20.35 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.90 | 2.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.30 | 2.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.75 | 2.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.41 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.07 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.95 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.13 | 1.4% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $6.15 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $944.67 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $176.94 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $141.15 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $107.14 | 7 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $81.42 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $81.42 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $81.42 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.56 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $46.50 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.15 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.45 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.25 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $25.63 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.86 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.13 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $6.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 19 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
620 | 64 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 803 | 150 |
| Eliquis | Apixaban | 620 | 64 |
| Gabapentin | Gabapentin | 475 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 465 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 380 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 370 | 71 |
| Sertraline Hcl | Sertraline Hcl | 330 | 51 |
| Metformin Hcl | Metformin Hcl | 293 | 41 |
| Lisinopril | Lisinopril | 287 | 45 |
| Furosemide | Furosemide | 286 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 284 | 36 |
| Potassium Chloride | Potassium Chloride | 273 | 52 |
| Famotidine | Famotidine | 240 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 232 | 46 |
| Buspirone Hcl | Buspirone Hcl | 210 | 37 |
| Losartan Potassium | Losartan Potassium | 210 | 37 |
| Mirtazapine | Mirtazapine | 204 | 36 |
| Levetiracetam | Levetiracetam | 203 | 27 |
| Trazodone Hcl | Trazodone Hcl | 195 | 44 |
| Donepezil Hcl | Donepezil Hcl | 189 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 163 | 31 |
| Carvedilol | Carvedilol | 157 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 157 | 30 |
| Jardiance | Empagliflozin | 151 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 27 |
| Memantine Hcl | Memantine Hcl | 132 | 15 |
| Divalproex Sodium | Divalproex Sodium | 130 | 33 |
| Xarelto | Rivaroxaban | 127 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 124 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 17 |
| Baclofen | Baclofen | 107 | 17 |
| Allopurinol | Allopurinol | 102 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 102 | 14 |
| Midodrine Hcl | Midodrine Hcl | 101 | 18 |
| Torsemide | Torsemide | 99 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 96 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 11 |
| Olanzapine | Olanzapine | 80 | 11 |
| Prednisone | Prednisone | 80 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | 13 |
| Risperidone | Risperidone | 72 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 20 |
| Alendronate Sodium | Alendronate Sodium | 69 | 12 |
| Bupropion Xl | Bupropion Hcl | 66 | 15 |
| Bumetanide | Bumetanide | 57 | suppressed |
| Omeprazole | Omeprazole | 57 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 55 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 53 | 20 |
| Spironolactone | Spironolactone | 52 | 13 |
| Trulicity | Dulaglutide | 52 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 13 |
| Finasteride | Finasteride | 48 | suppressed |
| Alprazolam | Alprazolam | 45 | 15 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 24 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Glimepiride | Glimepiride | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Latanoprost | Latanoprost | 40 | 14 |
| Tramadol Hcl | Tramadol Hcl | 40 | 12 |
| Celecoxib | Celecoxib | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | 13 |
| Ondansetron Odt | Ondansetron | 38 | 25 |
| Primidone | Primidone | 38 | suppressed |
| Sucralfate | Sucralfate | 38 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 37 | 12 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Scopolamine | Scopolamine | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 18 |
| Creon | Lipase/Protease/Amylase | 33 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 17 |
| Cimetidine | Cimetidine | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Ertapenem | Ertapenem Sodium | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 25 | suppressed |
| Valproic Acid | Valproic Acid | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Levemir | Insulin Detemir | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | 14 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 20 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 19 | 18 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 11 |
| Nyamyc | Nystatin | 19 | 14 |
| Xifaxan | Rifaximin | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 13 |
| Azithromycin | Azithromycin | 17 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 11 |
| Invega Sustenna | Paliperidone Palmitate | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Trospium Chloride | Trospium Chloride | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Clozapine | Clozapine | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $944.67 · 50 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, EVENITY, FARXIGA, Kerendia, LEQVIO, MAVYRET, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, QUTENZA, Rybelsus, SHINGRIX, SX-ONE MICROKNIFE, SYNTHROID, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error